Advances in topiramate as prophylactic treatment for migraine

It is well‐known that topiramate as a kind of antiepileptic drug has been proved effective for migraine prevention in North America and Europe. However, topiramate is still viewed as an off‐label medication for migraine treatment in China, partly because of the limited evidence in Chinese patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chuan, Zhang, Yixin, Tan, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553310/
https://www.ncbi.nlm.nih.gov/pubmed/34472696
http://dx.doi.org/10.1002/brb3.2290
_version_ 1784591552585138176
author Hu, Chuan
Zhang, Yixin
Tan, Ge
author_facet Hu, Chuan
Zhang, Yixin
Tan, Ge
author_sort Hu, Chuan
collection PubMed
description It is well‐known that topiramate as a kind of antiepileptic drug has been proved effective for migraine prevention in North America and Europe. However, topiramate is still viewed as an off‐label medication for migraine treatment in China, partly because of the limited evidence in Chinese patients. We summarize the effects of topiramate on the frequency, severity, quality‐of‐life, and adverse event among migraine patients, including children and adolescent in this review, so as to provide reference for Chinese doctors.
format Online
Article
Text
id pubmed-8553310
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85533102021-11-04 Advances in topiramate as prophylactic treatment for migraine Hu, Chuan Zhang, Yixin Tan, Ge Brain Behav Reviews It is well‐known that topiramate as a kind of antiepileptic drug has been proved effective for migraine prevention in North America and Europe. However, topiramate is still viewed as an off‐label medication for migraine treatment in China, partly because of the limited evidence in Chinese patients. We summarize the effects of topiramate on the frequency, severity, quality‐of‐life, and adverse event among migraine patients, including children and adolescent in this review, so as to provide reference for Chinese doctors. John Wiley and Sons Inc. 2021-09-02 /pmc/articles/PMC8553310/ /pubmed/34472696 http://dx.doi.org/10.1002/brb3.2290 Text en © 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Hu, Chuan
Zhang, Yixin
Tan, Ge
Advances in topiramate as prophylactic treatment for migraine
title Advances in topiramate as prophylactic treatment for migraine
title_full Advances in topiramate as prophylactic treatment for migraine
title_fullStr Advances in topiramate as prophylactic treatment for migraine
title_full_unstemmed Advances in topiramate as prophylactic treatment for migraine
title_short Advances in topiramate as prophylactic treatment for migraine
title_sort advances in topiramate as prophylactic treatment for migraine
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553310/
https://www.ncbi.nlm.nih.gov/pubmed/34472696
http://dx.doi.org/10.1002/brb3.2290
work_keys_str_mv AT huchuan advancesintopiramateasprophylactictreatmentformigraine
AT zhangyixin advancesintopiramateasprophylactictreatmentformigraine
AT tange advancesintopiramateasprophylactictreatmentformigraine

Ejemplares similares